Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VX 702

Drug Profile

VX 702

Alternative Names: KVK-702; VX-702

Latest Information Update: 27 May 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Kissei Pharmaceutical; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Phenylurea compounds
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Cardiovascular disorders; Rheumatoid arthritis

Most Recent Events

  • 31 Mar 2009 No development reported - Phase-I for Rheumatoid arthritis in Japan (PO)
  • 31 Mar 2009 No development reported - Phase-II for Rheumatoid arthritis in Europe (PO)
  • 14 Jun 2008 Pooled efficacy, pharmcaodynamic and safety data from two phase II trials in Rheumatoid arthritis presented at the Annual European Congress of Rheumatology (EULAR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top